Head-to-head evidence
Lazertinib vs SH-1028
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Lazertinib
Marketed by Johnson & Johnson and partners
NCT04248829 · Phase 3 · completed
The trial randomized 393 participants to lazertinib or an active gefitinib control and used quadruple masking, with investigators and outcome assessors blinded. Its primary clinical endpoint, progression-free survival, favored lazertinib numerically, but statistical significance is not reported, so the result cannot be classified as definitively met.
Next expected readout: December 2026 · NCT05463224 (registry estimate)
SH-1028
Developed by Nanjing Sanhome Pharmaceutical
NCT04239833 · Phase 3 · status unknown
In this randomized, double-blind, active-controlled Phase 3 trial in patients with EGFR-mutated non-small-cell lung cancer, SH-1028 significantly extended progression-free survival compared with gefitinib, the standard EGFR-targeted therapy (median 19.3 months vs 9.8 months).
Next expected readout: February 2028 · NCT06080776 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lazertinib's landscape · SH-1028's landscape